Abstract
Induced pluripotent stem cell (iPSC) technology holds great potential for therapeutic and research purposes. The Human Induced Pluripotent Stem Cell Initiative (HipSci) was established to generate a panel of high-quality iPSCs, from healthy and disease cohorts, with accompanying multi-omics and phenotypic data. Here, we present a proteomic analysis of 217 HipSci iPSC lines obtained from 163 donors.
This dataset provides a comprehensive proteomic map of iPSCs, identifying >16,000 protein groups. We analyse how the expression profiles of proteins involved in cell cycle, metabolism and DNA repair contribute to key features of iPSC biology and we identify potential new regulators of the primed pluripotent state. To facilitate access, all these data have been integrated into the Encyclopedia of Proteome Dynamics (www.peptracker.com/epd), where it can be browsed interactively. Additionally, we generated an iPSC specific spectral library for DIA which we deposited in PRIDE along with the raw and processed mass-spectrometry data.
Main text
A decade ago, Yamanaka and colleagues reported methods allowing the induction of Pluripotent Stem Cells (iPSCs) from human fibroblast cultures 1 . Their report showed that by exogenously expressing a small set of key transcription factors, a somatic cell could be reprogrammed back into a pluripotent state. These reprogrammed cells were shown to have the key features of their physiological embryonic stem cell (ESC) counterparts. Furthermore, since these reprogrammed stem cells can subsequently be differentiated into different somatic cell types, there is currently great interest in using iPSC technology to model human disease mechanisms and study development.
The Human Induced Pluripotent Stem Cells Initiative (HipSci) was established to generate and characterise a large, high-quality panel of human iPSCs, accompanied with detailed multi-omics and phenotypic characterisation. This involved the systematic derivation of iPSCs from many hundreds of healthy volunteer donors, along with disease cohorts, using a standardized and well-defined experimental pipeline that was previously described 2 .
Here, we provide a comprehensive, high-resolution proteomic map of human iPSCs, using lines generated by the HipSci consortium. Data are integrated from the quantitative, mass spectrometry-based analysis of 217 different iPSC lines derived from normal and disease cohorts. We provide a comprehensive proteomic overview of the human iPS cell type and explore how protein expression profiles account for key aspects of iPS cell biology affecting metabolism, cell cycle and DNA repair.
Additionally, by comparing protein expression between iPSC lines with either a 'High'
or 'Low' Pluritest 3 score, we identify potential new regulators of the primed pluripotent cell state.
To provide open access to all these data, the raw and the processed MS files,
together with a spectral library for DIA analysis of human iPSCs, have been deposited to the ProteomeXchange 4 PRIDE 5 repository (PXD010557), while the processed protein level data have been integrated into the Encyclopedia of Proteome Dynamics 6 , where it can be explored and analysed interactively. To provide a comprehensive overview of the human iPSC proteome, we used mass spectrometry-based (MS) quantitative proteomics to analyse 217 separate cell lines derived from 163 different donors. The iPSCs were all derived from human skin fibroblasts and reprogrammed as described previously 2 (illustrated in Fig. 1a ).
Results

Comprehensive Proteomic map of human iPSCs
To maximise throughput for the MS analysis, we combined high mass-accuracy MS with tandem mass tagging (TMT). This allowed the multiplexing of up to 10 cell lines in a single batch. The study was designed so that each batch contained 9 different iPSC lines and one common reference cell line, as shown in Fig.1a . The proteomic analysis of the 217 human iPSC lines was thus divided into 24 batches of 10plex-TMT experiments.
To maximize proteome coverage, a two-dimensional LC-MS strategy was used (see Methods). The first dimension was an off-line, basic reverse-phase HPLC fractionation step, separating the digested and TMT-labelled extracts from each iPSC line into 24 fractions. Each fraction was then analysed using online LC-MS on an Orbitrap Fusion MS. The resulting MS data were subsequently processed and quantified using the MaxQuant 7 suite.
In total, >16,000 protein groups were detected at 5% FDR (PSM and protein level).
This corresponds to detecting the expression of proteins encoded by over 10,500 different genes, representing 52% of all the human protein coding genes annotated within SwissProt. The depth of analysis achieved corresponds to a median protein sequence coverage of ~46% across all proteins (Fig.1b) . Furthermore, this depth of protein coverage was relatively constant across most chromosomes. For the majority of chromosomes, we detected >50% of their protein coding genes expressed in iPSCs (Fig. 1c) . Using the proteomic ruler, we detected wide differences in protein copy numbers expressed from different genes in iPS cells, spanning over 7 orders of magnitude, from <100 to ~100 million copies per cell (Fig. 1d) . This wide dynamic range of expression means the 15 most abundant proteins represent >10% of the total protein molecules in the iPS cell (Fig.1e) . These proteins include, as expected, histones, ribosomal proteins, translation factors and cytoskeletal components, which are abundant in most cell types. However, this hyper abundant group also includes two members of the glycolytic pathway, i.e. GAPDH (~45 million copies) and ENO1 (~18 million copies), along with the antioxidant PRDX1 (~15 million copies), whose abundances are more variable in differentiated cell types. Proteomic profile of cell cycle, DNA repair and metabolism , are highly abundant (>1,3 million copies) in iPS cells. Conversely, the iPSC lines had low levels of the CDK inhibitors (CDKIs), which repress cell cycle progression (Fig. 2a) . These observations help to explain how iPS cells achieve high rates of cell division.
Cell cycle
Increased expression of the CDK inhibitor CDKN1B is linked with lengthening of G1
and loss of pluripotency
18
. Consistent with the short G1 phase in iPSCs, our data
show that the expression level of CDKN1B is low, (<1,000 copies per cell). CDKN1B
was only detected in ~3% of lines, compared with both cyclin D1 (~91,000 copies per cell) and cyclin D2 (~24,000 copies), which are detected in ~70% with ~3.7 million copies per cell and XRCC1 ~350,000 copies.
In summary, we detect iPS cells expressing very high levels of a wide range of protein factors involved in the repair of DNA damage. This is consistent with the protection of iPSCs from an increased risk of DNA damage and mutation during rapid proliferation and subsequent differentiation.
Metabolism
1
The expression levels of key enzymes and molecules that control cell metabolism are highlighted in Fig. 2c , giving insights about the iPSC metabolic programs. All the iPSC lines expressed high levels of glycolytic enzymes. Glycolysis is inefficient for ATP production, compared with OXPHOS. Cells dependent upon glycolysis for energy metabolism therefore must sustain high levels of glucose uptake, which is reflected in the iPSC proteome by the high expression levels of multiple glucose transporters. For example, SLC2A1 (GLUT1) and SLC2A3 (GLUT3) are both present at ~500,000 copies per cell in all the iPSC lines. , is consistent with the high expression of LDHs and the PDC inhibitors, PDK1-3 (Fig. 2c) . The HipSci iPSC lines express high levels of both LDHA (~7 million copies) and LDHB (~13 million copies per cell). LDH isozymes have different affinity and inhibition patterns, with LDHB isozymes present in cells that are less inhibited by L-lactate 37 . Nonetheless L-lactate must still be removed by monocarboxylate transporters and our data show all iPSC lines have high levels (~1 million copies) of the lactate transporter SLC16A1. We also detect high expression of specific amino acid transporters, such as LAT1 (SLC7A5) (~635,000 copies) and its heavy subunit CD98 (SLC3A2) (~1,500,000 copies).
We detect abundant expression in iPSCs of the key enzymes of the PDC and TCA cycle. The PDC, which converts Pyruvate to Acetyl-CoA and is linked with histone acetylation and maintenance of pluripotency, hence is still vital for iPSCs 38 .
However, consistent with the lower reliance of iPSCs on OXPHOS, we also detect high expression of OXPHOS inhibitors, such as PDK1-3 and LIN28A/B 39 .
Furthermore, we detect expression of all enzymes in the Pentose Phosphate Pathway (PPP). Congruent with reports that iPSCs have preference for the nonoxidative side of the PPP 40 , we detect highest levels of the non-oxidative enzymes
Transketolase and Transaldolase, both expressed at >2 million copies per cell.
A feature of iPSCs is that they require high expression of antioxidants to reduce the oxidative stress caused by metabolism. In line with this requirement, our data show that the antioxidant PRDX1 is one of the most abundant proteins in all the iPSC lines, with ~16 million copies per cell. PRDX1 has been shown to regulate gene expression in response to ROS 41 .
Evaluating pluripotency and primed pluripotency markers
Human iPS cells share the hallmarks of primed pluripotency with their hESC counterparts, including the ability to self-renew and to differentiate into the three main germ layers. We initially evaluated the expression of 3 key factors known to maintain pluripotency and prevent spontaneous differentiation in primed iPSCs; i.e. SOX2, OCT4 and NANOG (Fig. 3a) . All 3 were expressed ubiquitously across nearly all iPSC lines. Focussing on iPSC lines derived from healthy donors, we used the Pluritest 3 score to stratify the lines into 'High' and 'Low' Pluritest score categories (see methods). We compared protein expression across the 'High' and 'Low' populations for 123 lines.
The levels of the 3 canonical pluripotency factors remained virtually identical between the two groups ( Fig. 3b) , consistent with the high QC within the HipSci pipeline 2 .
We evaluated proteomic changes within the two conditions and generated a Volcano plot comparing the 'High' vs 'Low' categories ( Fig. 4a ). The plot shows that the two populations are very similar. However, the statistical analysis revealed a subset of differentially expressed proteins affecting 3 main pathways, i.e. NF-kB, TGFB and RAS/RAF/ERK. The canonical FGF2-RAS/RAF/ERK pathway is vital to primed pluripotency 42 and our data show the core members remain virtually unchanged between populations.
However, we detect increased expression of MLK1/3. MLKs can phosphorylate and activate MEK, with MLK1 and MLK3 being the most effective at activating ERK 43 .
We also see an increase in the nuclear ERK phosphatase DUSP5, which is activated as a negative feedback control for ERK 44 
The Encyclopedia of Proteome Dynamics (EPD):
Interactive iPSC analysis and visualisation The EPD is an online database and web-application that provides open access to multi-omics data, featuring graphical navigation with interactive visualisations that enable data exploration in an intuitive, user-friendly manner
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. All of the processed iPSC proteomics data, has been integrated within the EPD ecosystem and is available at: https://peptracker.com/epd/analytics/?section_id=40100.
As illustrated in Fig. 5 , the EPD provides dynamic visualisations specifically created to analyse and explore the iPSC data. A dashboard presents an overview of the data for each specific protein, summarising correlation with RNA data, copy numbers and identification details (Fig. 5c ). Global views of the dataset are provided with histograms ( Fig. 5d ) and bubble plots (Fig. 5e) , both displaying the median protein copy numbers across all lines. For the Pluritest analysis, the Volcano plot ( Fig. 5f ),
showing p-values and log2 fold changes, is available interactively. We also integrated the iPSC dataset with the Reactome 53 Pathway widget for pathway analysis (Fig. 5g) and with the KinoViewer 8 , to explore kinase expression via the kinase phylogenetic tree (Fig. 4h ).
hiPSC spectral library To facilitate further MS analyses on human iPS cells, we also created a data independent acquisition (DIA) Spectral Library. To generate the library, an initial DDA workflow was set up (Fig. 6 ). Three representative iPSC lines were selected for in-depth analysis, via reversed-phase and HILIC chromatography. 24 fractions were analysed by LC-MS/MS on a Q-Exactive Plus Orbitrap mass-spectrometer in 'Label
Free' mode, with two technical replicates per line. The samples were spiked with the Biognosys IRT Kit to align retention time. In total, 288 raw files were collected and quantified using MaxQuant v 1.6.0.13. This output was used to generate the spectral library using Spectronaut.
The resulting human iPSC DIA library is compatible with Orbitrap MS platforms and with popular DIA software packages, e.g. Skyline and Spectronaut. This iPSC DIA library is freely available within the PRIDE submission (PXD010557).
Discussion
Human induced pluripotent stem cells have great potential for therapeutic and research applications, providing improved ethical models for studies on disease mechanisms and personalised regenerative medicine. We provide here a valuable research resource with the most in-depth proteome map of human iPSCs reported to date.
Our proteomic data provides insights into iPSC metabolism, highlighting the important role of glycolysis, along with elevated levels of glucose, amino acid and The proteomic data also help to explain the highly efficient DNA Damage Repair phenotype of iPS cells, which is important to prevent accumulation of mutations during proliferation and differentiation. Thus, we detect high expression levels of 0 members of the NHEJ and HR pathways, along with elevated expression of p53, which will trigger cell death should DNA damage not be corrected. Furthermore, we have generated a human iPSC spectral library, to support future proteomic studies on healthy and disease iPSCs lines using data independent acquisition (DIA). The iPSC spectral library is also freely available via the PRIDE repository. We are confident these data will provide a valuable resource that will facilitate further research and applications using human iPSCs.
Methods
Generation of iPSC lines
All lines included in this study are part of the HipSci resource and were reprogrammed from primary fibroblasts as previously described 2 . Out of the total of more than 800 iPSC lines available within the HipSci resource (www.hipsci.org), 217
lines, predominantly from healthy donors, were selected for in depth proteomic analysis in this study using Tandem Mass Tag Mass Spectrometry.
TMT Sample preparation
For protein extraction, iPSC cell pellets were washed with ice cold PBS and redissolved immediately in 200 μ L of lysis buffer (8 M urea in 100 mM triethyl ammonium bicarbonate (TEAB)) and mixed at room temperature for 15 minutes.
The DNA content of the cells is sheared using ultrasonication (6 X 20 s on ice). The proteins were reduced using tris-carboxyethylphosphine TCEP (25 mM) for 30 minutes at room temperature, then alkylated in the dark for 30 minutes using iodoacetamide (50 mM). Total protein was quantified using the EZQ assay (Life Technologies). The lysates were diluted with 100 mM TEAB 4-fold for the first digestion with mass spectrometry grade lysyl endopeptidase, Lys-C (Wako, Japan), then further diluted 2.5-fold before a second digestion with trypsin. Lys-C and trypsin were used at an enzyme to substrate ratio of 1:50 (w/w). The digestions were carried out overnight at 37ºC, then stopped by acidification with trifluoroacetic acid (TFA) to a final concentration of 1% (v:v). Peptides were desalted using C18 Sep-Pak cartridges (Waters) following manufacturer's instructions.
For tandem mass tag (TMT)-based quantification, the dried peptides were redissolved in 100 mM TEAB (50 μl) and their concentration was measured using a fluorescent assay (CBQCA, Life Technologies). 100 μg of peptides from each cell line to be compared, in 100 μl of TEAB, were labelled with a different TMT tag (20 μg ml −1 in 40 μl acetonitrile) (Thermo Scientific), for 2 h at room temperature.
After incubation, the labelling reaction was quenched using 8 μl of 5% hydroxylamine (Pierce) for 30 min and the different cell lines/tags were mixed and dried in vacuo.
The TMT samples were fractionated using off-line high-pH reverse-phase (RP) chromatography: samples were loaded onto a 4.6 × 250 mm Xbridge BEH130 C18 column with 3.5-μm particles (Waters). Using a Dionex bioRS system, the samples were separated using a 25-min multistep gradient of solvents A (10 mM formate at pH 9) and B (10 mM ammonium formate pH 9 in 80% acetonitrile), at a flow rate of 1 ml min −1 . Peptides were separated into 48 fractions, which were consolidated into 24 fractions. The fractions were subsequently dried and the peptides re-dissolved in 5% formic acid and analysed by LC-MS/MS.
TMT LC-MS/MS
TMT-based analysis. Samples were analysed using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific), equipped with a Dionex ultra-high-pressure liquidchromatography system (RSLCnano). RPLC was performed using a Dionex RSLCnano HPLC (Thermo Scientific). Peptides were injected onto a 75 µm × 2 cm PepMap-C18 pre-column and resolved on a 75 µm × 50 cm RP-C18 EASY-Spray temperature-controlled integrated column-emitter (Thermo Scientific), using a four- During the MS3 analysis for more accurate TMT quantifications, 5 fragment ions were co-isolated using synchronous precursor selection using a window of 2 Th and further fragmented using HCD collision energy of 55%. The fragments were then analysed in the orbitrap with a resolution of 60,000. The AGC target was set to 1.0 x 10 5 and the maximum injection time was set to 105 ms.
Accession codes
All of the mass-spectrometry data generated from the TMT batches, the DIA library, fasta file, and MaxQuant outputs have been uploaded to PRIDE (PXD10557).
Identification & Quantification
The TMT-labelled samples were collected and analysed using Maxquant 7, 57 v. 
Copy number generation
Every TMT batch had 1 control cell line (bubh3, reporter channel 0) and 9 sample cell lines. Protein copy numbers were calculated following the proteomic ruler 9 and using the MS3 intensity. To minimise potential batch effects, the protein copy numbers were normalised using the reference cell line present in every batch.
For every protein, the references lines in each TMT batch were used to calculate a median copy number, and then calculate a ratio between the control in every TMT batch and the median. All values within the batch were corrected via this ratio.
Lead razor protein assignment
The lead razor protein for each Protein Group was modified from the MaxQuant output. The number of peptides that could theoretically be assigned to each element of the protein groups were selected, and all the elements of the Protein Group with highest number of peptides were selected. If there was only one candidate protein, then this element became the lead razor protein, if multiple candidates were present additional filtering was required.
Among the candidates the priority was given to the canonical SwissProt entry, if no canonical entry was present it would default to a reviewed protein isoform. If no reviewed proteins isoforms were present among the candidate proteins, then the lead element would be assigned to a TrEMBL proteoform. A TrEMBL proteoform would only be assigned a lead protein role based on the previously described scenario.
Chromosome mapping
To map gene products to their specific chromosomes, we utilised the UniProt 58 protein-chromosome mapping file. We used the file to produce a list of unique protein coding genes for each specific chromosome. Subsequently, we mapped the proteins detected in our iPSC dataset to their corresponding chromosomes based on the UniProt mapping file and produced a list of genes for each chromosome as well.
We compared the iPSC specific list of genes, with the reference list to determine the percentage of protein coding genes detected in our iPSC dataset for each chromosome.
Statistical analysis
The Pluritest statistical analysis, illustrated on the volcano plot, was generated based on the copy number and Pluritest scores data. The lines were stratified into two categories, i.e. 'High' and 'Low', based on the median Pluritest score. Only proteins that were detected in at least two distinct TMT batches for each condition were selected for analysis. Additionally, 2 or more Unique and Razor peptides had to be assigned to the protein group.
P-values were calculated in R utilising the bioconductor package Linear Models for Microarray Data (LIMMA) version 3.7. The fold change used was also calculated by LIMMA and uses the Log 2 geometric mean. Q-values were generated in R using the "qvalue" package version 2.10.0
Dynamic visualisations within the EPD
All processed proteomic data were integrated into the Encyclopedia of Proteome Dynamics 6 (https://peptracker.com/epd/analytics/). The tabular data are stored within Cassandra, and the relationships between datasets and identified proteins were modelled and stored within Neo4j.
The EPD server runs on Django, while the front end is a mixture of Angular, jQuery and D3.js. All of the visualisations were generated via D3.js as a client-side JavaScript library. The Reactome 53 Pathway browser was integrated into the EPD using the Reactome JavaScript widget and Analysis Services.
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